VON WILLEBRAND DISEASE: Managed Care Opportunities to Apply New Guideline-Endorsed Identification and Management Strategies
Jointly provided by
    National Hemophilia Foundation   

This activity is supported by independent educational grants from Grifols and Takeda.
Live Webcast Dates
Wednesday, January 19, 2022 12:30pm – 2:00pm ET Webcast complete!
Friday, January 28, 2022 12:00pm – 1:30pm ET Webcast complete!
Wednesday, February 2, 2022 12:30pm – 2:00pm ET Webcast complete!

These live webcasts are now complete!
An on-demand CE archive is coming soon.

Until then, please visit www.impactedu.net for more free CE activities.

  • The pathophysiology and epidemiology of von Willebrand disease (VWD)
  • VWD treatment strategies
  • Benefit design strategies and coverage criteria
Christina Barrington, PharmD
VP of Pharmacy Programs
Priority Health
Maria Lopes, MD, MS
Former Chief Medical Officer
Magellan Health
Angela Weyand, MD
Clinical Assistant Professor, Department of Pediatrics and Communicable Diseases
University of Michigan
Marla Feinstein, MPH, PhD
Senior Policy and Healthcare Analyst
National Hemophilia Foundation
  • This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.

Bleeding disorders affect more than three million Americans by preventing the blood from clotting normally, potentially leading to prolonged bleeding after injury, surgery, and physical trauma. VWD is the most common bleeding disorder in the United States, although estimates of disease incidence vary significantly. As many as 2 in 100 individuals may be affected by VWD, with a similar frequency in both males and females; however, heavy menstrual bleeding (HMB) and post-partum hemorrhage (PPH) associated with this particular type of bleeding disorder make it more problematic in women. Considering the diverse physical and psychosocial complications associated with VWD, expert disease management is best delivered via the integrated care model implemented by hemophilia treatment centers (HTCs). This model deploys a multidisciplinary team of health care providers to address virtually every facet of care for patients with bleeding disorders.


At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Describe the pathophysiology and epidemiology of VWD
  • Identify the signs and symptoms of VWD as well as evidence-based assessment methodologies for the timely and accurate diagnosis of VWD
  • Review available VWD treatment strategies appropriate to disease subtype/severity
  • Evaluate benefit design strategies and coverage criteria that facilitate timely diagnosis, appropriate treatment, and overall cost management of VWD
Pre-Activity Learning Assessment and Opening Comments/Overview
Sarah Waite-Ardini, MA
The Pathophysiology, Epidemiology, and Treatment Strategies for von Willebrand disease (VWD)
Angela Weyand, MD
Application of Evidence-based VWD Guidelines in a Managed Care Setting
Christina Barrington, PharmD
VWD Benefit Design and Coverage Criteria that Facilitate Access to Quality Care
Maria Lopes, MD, MS
Audience Q&A Session
All Faculty
Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the National Hemophilia Foundation and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-22-144-L01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.